Does Dextrose Prolotherapy Work for Knee Arthritis?
- 19 hours ago
- 4 min read
By Dr. Jeffrey Peng, MD · Published March 6, 2026 · 5 min read
Watch the Full Video
Dextrose prolotherapy is one of the oldest regenerative injection therapies still in use today, yet most patients have never heard of it. The concept is simple: inject a concentrated sugar solution into or around a damaged joint to trigger the body’s natural healing response. But does the science actually support this approach for knee arthritis? In this post, we review the clinical trial evidence to answer that question — and explore how dextrose prolotherapy compares to other treatments like PRP injections.
What Is Dextrose Prolotherapy?
Prolotherapy — short for "proliferation therapy" — involves injecting a hypertonic solution into a damaged or degenerated joint to stimulate tissue repair. Dextrose, a type of sugar molecularly similar to glucose, is the most commonly used prolotherapy agent. The treatment works by creating a controlled inflammatory response that recruits chemical mediators and growth factors to promote local healing of injured tissues (Sert et al., 2020).
Despite sounding unconventional, dextrose prolotherapy has been in clinical use since the 1950s. The rationale is straightforward: by introducing a concentrated dextrose solution into the joint space and surrounding ligamentous structures, the resulting inflammatory cascade jumpstarts the body’s healing mechanisms in tissues that have stalled in a chronic degenerative state.
Does Dextrose Prolotherapy Reduce Knee Arthritis Pain?
A well-designed randomized controlled trial compared intra-articular dextrose prolotherapy to placebo saline injections in patients with knee osteoarthritis (Sit et al., 2020). Patients received injections at weeks 0, 4, 8, and 16, with outcomes measured at baseline, 4 months, 7 months, and 1 year. The results were encouraging: dextrose prolotherapy significantly reduced pain, improved physical function, and enhanced quality of life compared to blinded saline injections. The researchers also noted that the procedure was safe, straightforward, and that patient adherence and satisfaction were high.
To go beyond a single trial, a comprehensive meta-analysis pooled data from 14 randomized controlled trials involving 978 patients (Chen et al., 2022). The analysis found that dextrose prolotherapy produced favorable effects on pain, overall function, and quality of life compared to both placebo injections and noninvasive control therapies. Importantly, these benefits were observed across multiple follow-up time points, suggesting the effects are durable rather than short-lived.
The meta-analysis authors did note that some of the included studies carried a high risk of bias, so the results should be interpreted with appropriate caution. Nonetheless, the overall trend across 14 trials is clearly positive for dextrose prolotherapy.
How Does Dextrose Prolotherapy Compare to PRP Injections?
While dextrose prolotherapy shows promise on its own, an important clinical question is how it stacks up against platelet-rich plasma (PRP). A randomized double-blind trial directly compared these two treatments for knee osteoarthritis (Rahimzadeh et al., 2018). Patients received three injections — at baseline, one month, and two months — and were followed for six months.
Both groups showed significant improvements in pain scores, physical function, and quality of life shortly after the first injection. However, the patients who received PRP injections demonstrated substantially greater improvements across all outcome measures. The study confirmed that while prolotherapy is effective, PRP appears to deliver superior clinical results for knee arthritis.
Should You Consider Dextrose Prolotherapy for Knee Arthritis?
Based on the current clinical trial evidence, PRP remains the stronger injection option for treating knee osteoarthritis. However, dextrose prolotherapy is a worthwhile alternative — particularly for patients who cannot access PRP or for whom it is not a viable option. The treatment is safe, with none of the reviewed clinical trials reporting significant adverse effects, and dextrose solution itself is remarkably inexpensive.
Unfortunately, most insurance plans in the United States do not cover prolotherapy injections despite the growing evidence supporting their use. This stands in stark contrast to the continued coverage of cortisone injections, which carry well-documented risks of long-term joint harm. As more high-quality clinical trials are completed, there is hope that insurance policies will evolve to reflect the evidence and provide patients with access to regenerative treatments that actually work.
If you are considering dextrose prolotherapy or other regenerative medicine options for knee arthritis, schedule a consultation to discuss which treatment approach is best suited to your individual needs.
References
1. Sert AT, Sen EI, Esmaeilzadeh S, Ozcan E. The Effects of Dextrose Prolotherapy in Symptomatic Knee Osteoarthritis: A Randomized Controlled Study. J Altern Complement Med. 2020;26(5):409-417. doi:10.1089/acm.2019.0335
2. Sit RWS, Wu RWK, Rabago D, et al. Efficacy of Intra-Articular Hypertonic Dextrose (Prolotherapy) for Knee Osteoarthritis: A Randomized Controlled Trial. Ann Fam Med. 2020;18(3):235-242. doi:10.1370/afm.2520
3. Chen YW, Lin YN, Chen HC, Liou TH, Liao CD, Huang SW. Effectiveness, Compliance, and Safety of Dextrose Prolotherapy for Knee Osteoarthritis: A Meta-Analysis and Metaregression of Randomized Controlled Trials. Clin Rehabil. 2022;36(6):740-752. doi:10.1177/02692155221086213
4. Rahimzadeh P, Imani F, Faiz SHR, Entezary SR, Zamanabadi MN, Alebouyeh MR. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clin Interv Aging. 2018;13:73-79. doi:10.2147/CIA.S147757
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
Comments